February 13th 2025
As a result of an independent committee’s determination, the study has been discontinued.
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Burst CME™: Future Implications for the Treatment Landscape of Primary Biliary Cholangitis (PBC)
View More
Burst CME™: Reimagining Approaches to Treating Patients with Primary Biliary Cholangitis (PBC)
View More
Burst CME™: Enhancing Strategies for Diagnosing Primary Biliary Cholangitis (PBC)
View More
2025 International Symposium of Gastrointestinal Oncology (ISGIO)
September 12-13, 2025
Register Now!
Collaborating Across the Continuum™: Identifying and Preventing Hepatic Encephalopathy in Long-Term Care Settings
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
The Future of COVID-19 Vaccines, and Other Top Stories This Week
June 16th 2023This week, the FDA’s vaccine advisory committee unanimously voted the next generation of COVID-19 vaccines should be updated to a monovalent XBB strain. Read all about this and other top infectious disease headlines.
Read More
Rising Threat: Evaluating Salmonella Treatment Options Amid Antimicrobial Resistance
May 15th 2023Empiric therapy for severe Salmonella disease remains effective, but fluoroquinolone resistance calls for a shift towards trimethoprim-sulfamethoxazole as the preferred oral treatment for non-severe cases.
Read More
Patient Perspectives on Rectal Administration for Recurrent C difficile Infection
May 15th 2023A study of patients with recurrent Clostridioides difficile infection (rCDI) found that Rebyota, a rectally administered live biotherapeutic, was considered easy, quick, and appealing due to the lack of bowel preparation.
Read More
Seres Shares Trial Data for Vowst, the FDA-Approved Microbiome Therapeutic
May 8th 2023Recent phase 3 trial data for Vowst showed the microbiota-based therapeutic prevented recurrent C difficile infection in 91.3% of recipients after 8 weeks, a response that 94.6% of these patients maintained through week 24.
Read More